<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236441</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17070546</org_study_id>
    <secondary_id>1R21DK113486-01A1</secondary_id>
    <nct_id>NCT03236441</nct_id>
  </id_info>
  <brief_title>Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury</brief_title>
  <acronym>BRICK</acronym>
  <official_title>Biochemical and Reno-protective Effects of Remote Ischemic Pre-conditioning on Contrast-induced Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oladipupo Olafiranye, MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a prospective, double-blind, sham-controlled, randomized clinical trial to study the&#xD;
      effects of remote ischemic preconditioning on contrast-induced acute kidney injury, vascular&#xD;
      and renal biomarkers in patients with non-ST elevation myocardial infarction and unstable&#xD;
      angina undergoing cardiac catheterization and percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BRICK study is a prospective, double-blind, sham-controlled, randomized clinical trial in&#xD;
      patients with non-ST elevation myocardial infarction and unstable angina undergoing cardiac&#xD;
      catheterization and percutaneous coronary intervention who are at high risk for&#xD;
      contrast-induced acute kidney injury. The study will investigate the effects of remote&#xD;
      ischemic preconditioning before cardiac catheterization on rate of contrast induced acute&#xD;
      kidney injury and novel biomarkers of renal injury/protection within 48hrs of cardiac&#xD;
      catheterization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced acute kidney injury</measure>
    <time_frame>48 hours</time_frame>
    <description>Contrast-induced acute kidney injury is defined as a relative increase in serum creatinine of ≥ 0.3mg/dl at 48 hours post catheterization compared with initial creatinine before catheterization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers study</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Novel vascular and renal biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Contrast-induced Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>RIPC Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-RIPC Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RIPC</intervention_name>
    <description>Remote ischemic preconditioning</description>
    <arm_group_label>RIPC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham-RIPC</intervention_name>
    <description>Control</description>
    <arm_group_label>Sham-RIPC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with non-ST elevation myocardial infarction or unstable angina&#xD;
&#xD;
          -  Referral for cardiac catheterization and percutaneous coronary intervention&#xD;
&#xD;
          -  Contrast-induced acute kidney injury risk score of ≥11&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  unstable blood pressure (systolic blood pressure &gt; 200 or &lt;90 mmHg)&#xD;
&#xD;
          -  History of allergy to contrast media&#xD;
&#xD;
          -  Peripheral vascular disease of upper limb&#xD;
&#xD;
          -  Renal disease requiring dialysis&#xD;
&#xD;
          -  Placement of arteriovenous fistula and arteriovenous graft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oladipupo Olafiranye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brianna Carbone, RN</last_name>
    <phone>412-647-8305</phone>
    <email>lamarcab@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oussama Khalifa, MD</last_name>
    <phone>412-647-8305</phone>
    <email>khalifao3@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Carbone, RN</last_name>
      <phone>412-647-8305</phone>
      <email>lamarcab@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Oussama Khalifa, MD</last_name>
      <phone>4126478305</phone>
      <email>khalifao3@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oladipupo Olafiranye, MD</last_name>
      <phone>412-802-3131</phone>
      <email>olafiranyeo@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Oladipupo Olafiranye, MD, MS</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>remote ischemic conditioning</keyword>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>cardiac catheterization</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

